A phase IIa study to examining the efficacy of THX-110 [Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide (PEA)] for Chronic Low Back Pain.

Trial Profile

A phase IIa study to examining the efficacy of THX-110 [Dronabinol (synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide (PEA)] for Chronic Low Back Pain.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2018

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Back pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 May 2018 Status changed from planning to recruiting, according to a Therapix Biosciences media release.
    • 31 May 2018 According to a Therapix Biosciences media release, this investigator-initiated trial has been started at the Clinical Research Institute, TN, USA.
    • 23 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top